These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Killing of Leishmania donovani amastigotes by poly ICLC in hamsters. Bhakuni V; Singha UK; Dutta GP; Levy HB; Maheshwari RK J Interferon Cytokine Res; 1996 Apr; 16(4):321-5. PubMed ID: 9162526 [TBL] [Abstract][Full Text] [Related]
6. Immunochemotherapy for Leishmania donovani infection in golden hamsters: combinatorial action of poly ICLC plus L-arginine and sodium stibogluconate (Stibanate). Bhakuni V; Kulkarni S; Ali V; Singh UK; Levy HB; Maheshwari RK J Interferon Cytokine Res; 1999 Oct; 19(10):1103-6. PubMed ID: 10547149 [TBL] [Abstract][Full Text] [Related]
7. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Butowski N; Chang SM; Junck L; DeAngelis LM; Abrey L; Fink K; Cloughesy T; Lamborn KR; Salazar AM; Prados MD J Neurooncol; 2009 Jan; 91(2):175-82. PubMed ID: 18797818 [TBL] [Abstract][Full Text] [Related]
8. A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. Butowski N; Lamborn KR; Lee BL; Prados MD; Cloughesy T; DeAngelis LM; Abrey L; Fink K; Lieberman F; Mehta M; Ian Robins H; Junck L; Salazar AM; Chang SM J Neurooncol; 2009 Jan; 91(2):183-9. PubMed ID: 18850068 [TBL] [Abstract][Full Text] [Related]
9. [Effect of interferon inducer (poly ICLC) in the treatment of malignant brain tumor (author's transl)]. Nakamura O; Shitara N; Matsutani M; Takakura K; Machida H No To Shinkei; 1982 Mar; 34(3):267-73. PubMed ID: 7093065 [TBL] [Abstract][Full Text] [Related]
10. The efficacy of poly-ICLC against Ebola-Zaire virus (EBOV) infection in mice and cynomolgus monkeys. Kende M; Paragas J; Salazar AM Antiviral Res; 2019 Mar; 163():179-184. PubMed ID: 30611774 [TBL] [Abstract][Full Text] [Related]
11. Enhanced therapeutic efficacy of poly(ICLC) and ribavirin combinations against Rift Valley fever virus infection in mice. Kende M; Lupton HW; Rill WL; Levy HB; Canonico PG Antimicrob Agents Chemother; 1987 Jul; 31(7):986-90. PubMed ID: 3662477 [TBL] [Abstract][Full Text] [Related]
12. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. Okada H; Kalinski P; Ueda R; Hoji A; Kohanbash G; Donegan TE; Mintz AH; Engh JA; Bartlett DL; Brown CK; Zeh H; Holtzman MP; Reinhart TA; Whiteside TL; Butterfield LH; Hamilton RL; Potter DM; Pollack IF; Salazar AM; Lieberman FS J Clin Oncol; 2011 Jan; 29(3):330-6. PubMed ID: 21149657 [TBL] [Abstract][Full Text] [Related]
13. Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients. Ishikawa T; Kageyama S; Miyahara Y; Okayama T; Kokura S; Wang L; Sato E; Yagita H; Itoh Y; Shiku H Cancer Immunol Immunother; 2021 Nov; 70(11):3081-3091. PubMed ID: 33751208 [TBL] [Abstract][Full Text] [Related]
14. Treatment of recurrent laryngeal papillomatosis with an artificial interferon inducer (poly ICLC). Leventhal BG; Kashima H; Levine AS; Levy HB J Pediatr; 1981 Oct; 99(4):614-6. PubMed ID: 7277106 [No Abstract] [Full Text] [Related]
15. Cortisol induction by poly ICLC: implications for clinical trials of interferon. Bever CT; McFarland HF; Levy HB; McFarlin DE Ann Neurol; 1988 Feb; 23(2):196-9. PubMed ID: 2454067 [TBL] [Abstract][Full Text] [Related]
16. Preliminary trial of poly ICLC in chronic progressive multiple sclerosis. Bever CT; Salazar AM; Neely E; Ferraraccio BE; Rose JW; McFarland HF; Levy HB; McFarlin DE Neurology; 1986 Apr; 36(4):494-8. PubMed ID: 3960323 [TBL] [Abstract][Full Text] [Related]
17. A comparison of interferon responses to poly ICLC in males and females. Bever CT; McFarlin DE; Levy HB J Interferon Res; 1985; 5(3):423-8. PubMed ID: 2414373 [TBL] [Abstract][Full Text] [Related]
18. Ketoconazole, a cytochrome P(450) inhibitor can potentiate the antimalarial action of α/β arteether against MDR Plasmodium yoelii nigeriensis. Tripathi R; Rizvi A; Pandey SK; Dwivedi H; Saxena JK Acta Trop; 2013 May; 126(2):150-5. PubMed ID: 23391499 [TBL] [Abstract][Full Text] [Related]
19. Plasmodium yoelii nigeriensis (MDR)-efficacy of oral pyronaridine against multidrug-resistant malaria in Swiss mice. Tripathi R; Umesh A; Mishra M; Puri SK; Dutta GP Exp Parasitol; 2000 Mar; 94(3):190-3. PubMed ID: 10831384 [TBL] [Abstract][Full Text] [Related]
20. Response of mouse tumor to interferon inducer and radiation. Lvovsky EA; Mossman KL; Levy HB; Dritschilo A Int J Radiat Oncol Biol Phys; 1985 Sep; 11(9):1721-5. PubMed ID: 4030439 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]